ATE295367T1 - Doppelsträngiges oligonukleotid und karzinostatisches mittel das dieses als aktiven inhaltsstoff enthält - Google Patents
Doppelsträngiges oligonukleotid und karzinostatisches mittel das dieses als aktiven inhaltsstoff enthältInfo
- Publication number
- ATE295367T1 ATE295367T1 AT95938023T AT95938023T ATE295367T1 AT E295367 T1 ATE295367 T1 AT E295367T1 AT 95938023 T AT95938023 T AT 95938023T AT 95938023 T AT95938023 T AT 95938023T AT E295367 T1 ATE295367 T1 AT E295367T1
- Authority
- AT
- Austria
- Prior art keywords
- active ingredient
- stranded oligonucleotide
- double stranded
- agent containing
- containing same
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/13—Decoys
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP28306594 | 1994-11-17 | ||
PCT/JP1995/002348 WO1996016074A1 (fr) | 1994-11-17 | 1995-11-16 | Oligonucleotide bicatenaire et agent carcinostatique le contenant en tant que constituant actif |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE295367T1 true ATE295367T1 (de) | 2005-05-15 |
Family
ID=17660755
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT95938023T ATE295367T1 (de) | 1994-11-17 | 1995-11-16 | Doppelsträngiges oligonukleotid und karzinostatisches mittel das dieses als aktiven inhaltsstoff enthält |
Country Status (7)
Country | Link |
---|---|
US (1) | US6034234A (de) |
EP (1) | EP0733640B1 (de) |
JP (1) | JP3392143B2 (de) |
AT (1) | ATE295367T1 (de) |
AU (1) | AU3881095A (de) |
DE (1) | DE69534197T2 (de) |
WO (1) | WO1996016074A1 (de) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050164240A1 (en) * | 2003-10-06 | 2005-07-28 | Corgentech, Inc. | E2F oligonucleotide decoy molecules |
US7482158B2 (en) * | 2004-07-01 | 2009-01-27 | Mathison Brian H | Composite polynucleic acid therapeutics |
CA2583576A1 (en) | 2004-10-22 | 2006-04-27 | Anges Mg, Inc. | Chimera (double) decoy |
JPWO2006132204A1 (ja) | 2005-06-06 | 2009-01-08 | アンジェスMg株式会社 | 転写因子デコイ |
EP1978096A1 (de) * | 2005-12-22 | 2008-10-08 | Genomidea Inc | Neues oligonukleotid und dieses umfassender nf-kappa-b-köder |
US7943591B2 (en) | 2007-05-11 | 2011-05-17 | Adynxx, Inc. | Gene expression and pain |
EP2266626B1 (de) | 2008-03-28 | 2014-06-18 | AnGesMG, Inc. | Zusammensetzung zur topischen anwendung mit einem transkriptionsfaktor-decoy als wirkstoff |
ES2724851T3 (es) | 2012-05-10 | 2019-09-16 | Adynxx Inc | Formulaciones para el suministro de principios activos |
EP3180434B1 (de) | 2014-08-15 | 2019-07-17 | Adynxx, Inc. | Oligonukleotidköder zur behandlung von schmerz |
WO2017068790A1 (ja) * | 2015-10-23 | 2017-04-27 | レナセラピューティクス株式会社 | 核酸複合体 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06509704A (ja) * | 1991-04-18 | 1994-11-02 | ザ ソールク インスチチュート フォア バイオロジカル スタディズ | 特定dna配列に選択的に結合する蛋白質に対する偽構築体として有用なオリゴデオキシヌクレオチドおよびオリゴヌクレオチド |
NZ246432A (en) * | 1991-12-16 | 1996-06-25 | Genentech Inc | Fibrin-specific t-pa with a point mutation at position 276, vector cell cultures |
US5759803A (en) * | 1992-05-13 | 1998-06-02 | Dana-Farber Cancer Institute | Recombinant retinoblastoma-associated protein 1 (E2F-1) polypeptides and cDNA |
US5585479A (en) * | 1992-07-24 | 1996-12-17 | The United States Of America As Represented By The Secretary Of The Navy | Antisense oligonucleotides directed against human ELAM-I RNA |
US5859226A (en) * | 1993-07-29 | 1999-01-12 | Regents Of The University Of California, The | Polynucleotide decoys that inhibit MHC-II expression and uses thereof |
US5473056A (en) * | 1993-10-13 | 1995-12-05 | Merck & Co., Inc. | E2F-2, a novel mammalian transcription factor |
EP1340505A3 (de) * | 1993-10-29 | 2004-07-14 | The Brigham And Women's Hospital, Inc. | Therapeutische Verwendung von cis-Element-Fallen in vivo |
WO1995024223A1 (en) * | 1994-03-08 | 1995-09-14 | Thomas Jefferson University | Inhibition of cell proliferation by e2f-1 antisense oligonucleotides |
US5563036A (en) * | 1994-04-29 | 1996-10-08 | Tularik, Inc. | Transcription factor-DNA binding assay |
US5496831A (en) * | 1994-05-13 | 1996-03-05 | The General Hospital Corporation | Inhibition of insulin-induced adiposis |
-
1995
- 1995-11-16 AT AT95938023T patent/ATE295367T1/de not_active IP Right Cessation
- 1995-11-16 AU AU38810/95A patent/AU3881095A/en not_active Abandoned
- 1995-11-16 DE DE69534197T patent/DE69534197T2/de not_active Expired - Fee Related
- 1995-11-16 EP EP95938023A patent/EP0733640B1/de not_active Expired - Lifetime
- 1995-11-16 WO PCT/JP1995/002348 patent/WO1996016074A1/ja active IP Right Grant
- 1995-11-16 JP JP51672996A patent/JP3392143B2/ja not_active Expired - Fee Related
- 1995-11-16 US US08/676,241 patent/US6034234A/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP0733640A4 (de) | 1999-11-24 |
AU3881095A (en) | 1996-06-17 |
DE69534197T2 (de) | 2006-02-16 |
DE69534197D1 (de) | 2005-06-16 |
JP3392143B2 (ja) | 2003-03-31 |
EP0733640A1 (de) | 1996-09-25 |
US6034234A (en) | 2000-03-07 |
WO1996016074A1 (fr) | 1996-05-30 |
EP0733640B1 (de) | 2005-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BE904421A (fr) | Derives heterocycliques aromatiques et leur application dans les domaines therapeutique et cosmetique. | |
IS4073A (is) | Nýtt fjölvirknislyf gegn aukningu mótstöðu | |
BR9811260A (pt) | Pequenas moléculas úteis no tratamento de doença inflamatória | |
EE03681B1 (et) | Asendatud imidasoolid, millel on vähivastane ja tsütokiine inhibeeriv toime | |
DE69713526D1 (de) | Lösliche prodrugs von paclitaxel | |
ATE214072T1 (de) | Oligonukleotid und kanzerostatisches mittel das dieses als aktiven inhaltstoff enthält | |
TR199901259T2 (xx) | Nos inhibit�rleri olarak fayda ta��yan 6-fenilpiridil-2-amin t�revleri | |
MA26723A1 (fr) | Acides oxamiques nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant | |
DE69535805D1 (de) | Neue Carbamate- und Harnstoffderivate als Mittel gegen Multidrugresistenz | |
MA27002A1 (fr) | Amides d'acide anthranilique, procede pour les preparer, leur utilisation comme antiarythmiques et preparations pharmaceutiques les contenant | |
FR2856294B1 (fr) | Utilisation cosmetique d'une composition comprenant au moins une oxazoline, a titre de principe actif, comme amincissant et/ou pour prevenir et/ou traiter la cellulite | |
PT902789E (pt) | Derivados de androsteno | |
BR0207487A (pt) | Método de tratamento de tumores em mamìferos e uso de compostos de epotilona | |
BG104899A (en) | Antipicornaviral compounds and compositions, their pharmaceutical use and materials for their synthesis | |
ATE295367T1 (de) | Doppelsträngiges oligonukleotid und karzinostatisches mittel das dieses als aktiven inhaltsstoff enthält | |
ATE82681T1 (de) | 2',3'-dideoxy-3'-fluorothymidin und verwandte verbindungen zur behandlung von adenovirusinfektionen. | |
NL300198I1 (nl) | Toepassing van 2-(2-nitro-4-trifluormethylbenzoyl)cyclohexaandion-1,3 voor het behandelen van tyrosinemie, alsmede farmaceutische preparaten. | |
AU3902299A (en) | Methods of treating microbial infection and therapeutic formulations therefor | |
MX9805705A (es) | Compuestos biaromaticos, composiciones farmaceuticas y cosmeticas que los contienen y utilizaciones. | |
FR2711140B1 (fr) | 1-Naphtylpyrazole-3-carboxamides substitués actifs sur la neurotensine, leur préparation, les compositions pharmaceutiques en contenant. | |
CA2216569A1 (fr) | Utilisation de derives d'oxazolidinone comme agents anti-penetrants dans une composition cosmetique et/ou dermatologique | |
FR2713637B1 (fr) | Nouveaux composés bi-aromatiques dérivés d'amide, compositions pharmaceutiques et cosmétiques les contenant et utilisations. | |
ATE478686T1 (de) | Medikamente für massive tumore, welche inhibitoren der expression des wilms' tumorgens enthalten | |
KR950031085A (ko) | 표피증식 질환 치료용 의약 조성물 | |
BRPI0413684A (pt) | compostos, composição farmacêutica e respectivos métodos de preparação, de tratamento de infecção microbiana e de extermìnio de microrganismo e usos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |